| [1] | 世界卫生组织.[2022-10-27]. https://www.who.int/zh/news-room/fact-sheets/detail/tuberculosis. |
| [1] | WHO World Health Organization. [2022-10-27]. https://www.who.int/zh/news-room/fact-sheets/detail/tuberculosis. |
| [2] | 中国疾病预防控制中心. [2022-05-26]. https://www.chinacdc.cn/jkzt/crb/zl/jhb/jszl-2221. |
| [2] | Chinese Center for Disease Control and Prevention. [2022-05-26]. https://www.chinacdc.cn/jkzt/crb/zl/jhb/jszl-2221. |
| [3] | Van den Driessche P, Zou X. Modeling relapse in infectious diseases. Mathematical Biosciences, 2007, 207(1): 89-103 |
| [4] | Wallis R S. Mathematical models of tuberculosis reactivation and relapse. Frontiers in Microbiology, 2016, 7: Article 669 |
| [5] | Liu L, Zhang J, Li Y, Liu X. On the global stability of an age-structured tuberculosis transmission model with relapse. Mathematical Methods in the Applied Sciences, 2022, 45(9): 5622-5630 |
| [6] | Miao H, Xia X, Perelson A S, Wu H. On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Review, 2011, 53(1): 3-39 |
| [7] | Cao H, Gao X, Yan D, Zhang S. The dynamics of an age-structured TB transmission model with relapse. Mathematical Methods in the Applied Sciences, 2020, 43(6): 3807-3826 |
| [8] | Tuncer N, Gulbudak H, Cannataro V L, Martcheva M. Structural and practical identifiability issues of immuno-epidemiological vector-host models with application to rift valley fever. Bulletin of Mathematical Biology, 2016, 78: 1796-1827 |
| [9] | Guillén-González F, Sevillano-Castellano E, Suárez A. Fitting parameters and therapies of ODE tumor models with senescence and immune system. Journal of Mathematical Biology, 2023, 87(5): Article 67 |
| [10] | 国家统计局. [2017]. http://www.stats.gov.cn/tjst/ndsj/. |
| [10] | National Bureau of Statistics. [2017]. http://www.stats.gov.cn/tjst/ndsj/. |
| [11] | 全国结核病学抽样调查技术指导组. 2000年全国结核病流行病学抽样调查报告. 中国防痨杂志, 2022, 4: 65-66 |
| [11] | National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis. Report on nationwide random survey for the epidemiology of tuberculosis in 2000. Chinese Journal of Tuberculosis Prevention, 2002, 4: 65-66 |
| [12] | 全球结核病报告. [2018]. http://www.who.int/tb/publications/global{-}report/en/. |
| [12] | Global Tuberculosis Report. [2018]. http://www.who.int/tb/publications/global{-}report/en/. |
| [13] | Tuncer N, Timsina A, Nuno M, et al. Parameter identifiability and optimal control of an SARS-CoV-2 model early in the pandemic. Journal of Biological Dynamics, 2022, 16(1): 412-438 |
| [14] | Renardy M, Kirschner D, Eisenberg M. Structural identifiability analysis of age-structured PDE epidemic models. Journal of Mathematical Biology, 2022, 84(1): Article 9 |
| [15] | Gulbudak H, Qu Z, Milner F, Tuncer N. Sensitivity analysis in an immuno-epidemiological vector-host model. Bulletin of Mathematical Biology, 2022, 84(2): Article 27 |
| [16] | 邓萌, 徐瑞. 一类具有 CTL 免疫反应和免疫损害的 HIV 感染动力学模型的稳定性分析. 数学物理学报, 2022, 42A(5): 1592-1600 |
| [16] | Deng M, Xu R. Stability analysis of an HIV infection dynamic model with CTL immune response and immune impairment. Acta Math Sci, 2022, 42A(5): 1592-1600 |
| [17] | 张洪铎. 个体化治疗耐多药肺结核失败的影响因素分析. 临床合理用药杂志, 2017, 15: 108-109 |
| [17] | Zhang H Z. Analysis of the influencing factors of individualized treatment failure for multidrug-resistant pulmonary tuberculosis. Journal of Clinical Rational Drug Use, 2017, 15: 108-109 |
| [18] | 张雪元. 利福喷丁与利福平在肺结核治疗中的药效比较及安全性分析. 中国医药指南, 2021, 1: 36-37 |
| [18] | Zhang X Y. Comparison of efficacy and safety analysis of rifampicin and rifampicin in the treatment of pulmonary tuberculosis. Guide of China Medicine, 2021, 1: 36-37 |